StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report issued on Saturday morning. The firm issued a sell rating on the stock.
Navidea Biopharmaceuticals Stock Performance
NAVB stock opened at $0.04 on Friday. The firm has a 50 day moving average of $0.04 and a 200-day moving average of $0.05. Navidea Biopharmaceuticals has a 12-month low of $0.02 and a 12-month high of $0.30. The company has a market cap of $4.00 million, a price-to-earnings ratio of -0.57 and a beta of 1.13.
Institutional Trading of Navidea Biopharmaceuticals
An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. State Street Corp grew its stake in Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) by 1,631.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 412,743 shares of the company’s stock after purchasing an additional 388,900 shares during the quarter. State Street Corp owned approximately 1.18% of Navidea Biopharmaceuticals worth $38,000 as of its most recent filing with the SEC. 0.01% of the stock is owned by hedge funds and other institutional investors.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
See Also
- Five stocks we like better than Navidea Biopharmaceuticals
- What Does Downgrade Mean in Investing?
- Silicon Motion Proves That AI in Motion Stays in Motion
- Where to Find Earnings Call Transcripts
- Undervalued UnitedHealth Group Won’t Be For Long
- Compound Interest and Why It Matters When Investing
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.